课题基金 / 基金详情

项目摘要

项目成果

Peter M. Eimon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A major concern regarding drugs in development is cardiac toxicity. Commonly, drugs in development can cause changes to cardiac contractility, the force with which the heart beats, and cardiac rhythmicity, resulting in toxic side effects. The purpose of this Phase 1 proposal is to develop zebrafish assays for measuring drug-induced changes in cardiac contractility and cardiac rhythmicity. These assays will be developed using a transgenic zebrafish line expressing a green fluorescent reporter protein specifically in the heart. Methods of assessing contractility and rhythmicity in zebrafish will be developed. Drugs that are known to cause changes to cardiac contractility and rhythmicity in humans will be tested using these zebrafish in order to validate the assay. Development of these assays will allow high-throughput, in vivo testing of drugs in development for cardiac toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Zebrafish Assay for Parkinson's Disease Drugs
  • 批准号:
    7157349
  • 项目类别:
  • 资助金额:
    $16.11万
  • 财政年份:
    2006
  • 负责人:
    Peter M. Eimon
  • 依托单位:
Compound Screening in Z-Tag Zebrafish Angiogenesis Assay
  • 批准号:
    7405028
  • 项目类别:
  • 资助金额:
    $69.28万
  • 财政年份:
    2005
  • 负责人:
    Peter M. Eimon
  • 依托单位:
Zebrafish Lipid Metabolism Assay for Drug Screening
  • 批准号:
    7107276
  • 项目类别:
  • 资助金额:
    $65.75万
  • 财政年份:
    2003
  • 负责人:
    Peter M. Eimon
  • 依托单位:
海外基金